Incessant ovulation and ovarian cancer - a hypothesis re-visited

被引:0
|
作者
Fathalla, M. F. [1 ]
机构
[1] Assiut Univ, Obstet & Gynaecol, PO 30, Assiut, Egypt
关键词
Incessant ovulation; prevention; oral contraception; ovarian cancer;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian cancer continues to be a silent killer. Most women have advanced disease at the time of diagnosis. Intensive efforts to develop effective screening strategies have not so far met with success. There is a need to re-visit the potential of prevention strategies. In 1971, the author submitted a hypothesis for a possible relationship between incessant ovulation and development of epithelial ovarian cancer. Subsequent research from different disciplines opened new frontiers to be explored for prevention in the general population and in high-risk groups, and for opportunistic interventions. The protective effect of oral contraceptive pills has been well documented. Widespread use of the pill in the past several decades is credited with a fall in the incidence of ovarian cancer in the general population, countering the effect of low parity. Removing the barriers against contraceptive access and satisfying the still unmet contraceptive need could expand the protective coverage. Enhanced understanding of the biological mechanisms involved in process of ovulation offers the promise of non-hormonal pharmacologic suppression of follicle rupture for women who have risk factors and do not need contraception. The evidence for a possible origin of epithelial cancer in the fimbria of the Fallopian tube presents an opportunity for preventive intervention, during hysterectomy, where salpingectomy alone may provide protection while one or both ovaries are conserved. Finally, the incessant ovulator egg-laying hen has demonstrated its potential as an experimental model for chemoprevention of epithelial ovarian cancer.
引用
收藏
页码:292 / 297
页数:6
相关论文
共 50 条
  • [31] Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer
    G. Mangili
    M. Picchio
    S. Sironi
    R. Viganò
    E. Rabaiotti
    D. Bornaghi
    V. Bettinardi
    C. Crivellaro
    C. Messa
    F. Fazio
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 658 - 666
  • [32] Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer
    Mangili, G.
    Picchio, M.
    Sironi, S.
    Vigano, R.
    Rabaiotti, E.
    Bornaghi, D.
    Bettinardi, V.
    Crivellaro, C.
    Messa, C.
    Fazio, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (05) : 658 - 666
  • [33] Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis
    Nomiri, Samira
    Karami, Hassan
    Baradaran, Behzad
    Javadrashid, Darya
    Derakhshani, Afshin
    Nourbakhsh, Niloufar Sadat
    Shadbad, Mahdi Abdoli
    Solimando, Antonio Giovanni
    Tabrizi, Neda Jalili
    Brunetti, Oronzo
    Nasseri, Saeed
    Racanelli, Vito
    Safarpour, Hossein
    Silvestris, Nicola
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [34] Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
    McCann, Georgia A.
    Smith, Blair
    Backes, Floor J.
    Rath, Kellie
    Chacko, Simi
    Salani, Ritu
    Eisenhauer, Eric
    Fowler, Jeffrey M.
    Cohn, David E.
    O'Malley, David M.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (02) : 362 - 366
  • [35] Olaparib dose re-escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: A case series
    Ngu, Siew-Fei
    Tse, Ka-Yu
    Chu, Mandy M. Y.
    Ngan, Hextan Y. S.
    Chan, Karen K. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 3 - 11
  • [36] Re-Sensitization of Resistant Ovarian Cancer SKOV3/CDDP Cells to Cisplatin by Curcumin Pre-Treatment
    Hasan, Aseel Ali
    Kalinina, Elena
    Zhdanov, Dmitry
    Volodina, Yulia
    Tatarskiy, Victor
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [37] Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation
    Kessous, Roy
    Matanes, Emad
    Laskov, Ido
    Wainstock, Tamar
    Abitbol, Jeremie
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2021, 100 (03) : 453 - 458
  • [38] Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo
    Yukita, A
    Asano, M
    Okamoto, T
    Mizutani, S
    Suzuki, H
    ANTICANCER RESEARCH, 2000, 20 (1A) : 155 - 160
  • [39] Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate
    J. Vorwergk
    M. P. Radosa
    K. Nicolaus
    N. Baus
    J. Jimenez Cruz
    M. Rengsberger
    M. Gajda
    H. Diebolder
    I. B. Runnebaum
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 859 - 865
  • [40] [Re-186]-labeled mouse and chimeric monoclonal antibody 323/A3: A comparison of the efficacy in experimental human ovarian cancer
    Kievit, E
    vanGog, FB
    Schluper, HMM
    vanDongen, GAMS
    Pinedo, HM
    Boven, E
    NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (01) : 37 - 45